AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06280014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.
Study NCT06280014 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
Study NCT06391528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversalis Fascia Plane Block
Description: application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
Study NCT04241874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Respiratory support through mechanical ventilator
Study NCT04747275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liquid stable levothyroxine (L-T4) Tirosint-SOL
Description: Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
Study NCT04747275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral tablet levothyroxine (L-T4)
Description: Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
Study NCT05297721 — intervention group
Intervention type: OTHER
Intervention: Knowledge
Description: Measuring the level of knowledge about skin tears
Study NCT05601635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ButyraGen™
Description: ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
Study NCT06381440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat device (Hocoma AG, Volketswil, Switzerland).
Description: Robot Assisted Gait Training device
Study NCT06381440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat device (Hocoma AG, Volketswil, Switzerland).
Description: Robot Assisted Gait Training device
Study NCT06381440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking training
Description: Self-paced supervised walking training
Study NCT04897321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous
Study NCT04897321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
Study NCT04897321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MESNA
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
Study NCT04897321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: B7-H3 CAR T cells
Description: The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
Study NCT05139797 — intervention group
Intervention type: OTHER
Intervention: EchoNet-LVH screening for cardiac amyloidosis
Description: An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.
Study NCT06562569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive cervical vagal nerve stimulation ncVNS
Description: The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
Study NCT06170957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified pacifier
Description: In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times.
Study NCT05773131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR collaborative visualization system
Description: Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
Study NCT06364163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herring oil concentrate
Description: Capsules containing herring oil concentrate, taken daily for 8 weeks.
Study NCT06364163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Capsules containing control oil, taken daily for 8 weeks.
Study NCT05891821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody
Study NCT05486234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias
Description: Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
Study NCT05486234 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
Description: Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
Study NCT05408000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketofol vs propofol
Description: Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
Study NCT04833439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Low-caloric, low-protein, plant-based diet regiment for 3 days
Study NCT06393283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragm Training
Description: Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
Study NCT05411302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental health supportive text messages
Description: Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
Study NCT06124079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPY interactive messaging service
Description: 3 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The three versions differ in the motivational techniques interspersed throughout the OPY experience.
Study NCT06124079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
Study NCT05147779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05557318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swab for RT-PCR
Description: Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
Study NCT05557318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swab for culture
Description: Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
Study NCT05557318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metabolic gas signatures detected by Ainos Flora (operated by participant)
Description: The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
Study NCT05557318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metabolic gas signatures detected by Ainos Flora (operated by medical staff)
Description: The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
Study NCT04506112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation
Description: Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
Study NCT06044324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
Study NCT05304364 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Product: Naltrexone
Description: Naltrexone Implant
Study NCT05765097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas treatment
Description: five to seven days treatment by artificial pancreas system
Study NCT05856240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Stress & Emotions Group (MSEG)
Description: The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul \& Caver, 2021 for original protocol description).
Study NCT06288035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
Study NCT06288035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
Study NCT05600127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 3 cycles of avelumab (800mg, every 2 weeks)
Study NCT04473807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation
Description: The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
Study NCT05684276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center.
Study NCT05684276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study NCT05684276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Study NCT06391190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel, cisplatin, Sintilimab
Description: with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
Study NCT06221527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
Study NCT05772351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized flavonoid fraction
Description: Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work.
Study NCT05564338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally
Study NCT04800757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual -Brief Motivational Intervention (BMI)
Description: A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey.